Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
1 hedge funds and large institutions have $170K invested in Sonnet BioTherapeutics in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 27 closing their positions.
10.77% less ownership
Funds ownership: 11.29% → 0.53% (-11%)
95% less capital invested
Capital invested by funds: $3.53M → $170K (-$3.36M)
96% less funds holding
Funds holding: 27 → 1 (-26)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$687K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$441K |
| 3 |
HF
HRT Financial
New York
|
-$340K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$283K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$258K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| – | -$568 | -175 | Closed |
|
27
Citigroup
New York
| – | -$614 | -134 | Closed |
|
|
CWA
28
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
| – | -$147 | -32 | Closed |
|
SONN Hedge Fund Activity: Q4 2025 in Review
1 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2025, worth a combined $170K — down 95% from $3.53M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of SONN and 1 opened new positions — a net loss of 26 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Formidable Asset Management, opening a new position worth an estimated $168K. The largest seller was Ikarian Capital, exiting entirely with an estimated $687K sold.
- 1 institutional investor held Sonnet BioTherapeutics (SONN) as of Q4 2025, down from 27 in Q3 2025.
- Funds reported $170K of Sonnet BioTherapeutics stock for Q4 2025, down 95% quarter-over-quarter.
- 1 fund opened new Sonnet BioTherapeutics positions in Q4 2025 and 27 closed out, a net change of -26 holders.
- The largest Sonnet BioTherapeutics buyer in Q4 2025 was Formidable Asset Management, an estimated $168K added.
- The largest Sonnet BioTherapeutics seller in Q4 2025 was Ikarian Capital, an estimated $687K sold.
Based on aggregated 13F filings for Q4 2025.